A guideline already recommends to control disease activity to lower cardiovascular risk in patients with RA (28), as meta-analyses identified that the use of tumor necrosis factor inhibitors is beneficial to reduce the risk of cardiovascular events in patients with RA (29, 30). The gene discussed is TNF; the disease is rheumatoid arthritis.